While shares of Johnson & Johnson (NYSE:JNJ) have struggled since the start of 2016, investors have been looking to today’s fourth quarter earnings report hoping for some good news for once.
Well that report is now out, and it’s really a mixed bag of both positive and negative news. While the company posted an EPS of $1.15, beating analyst estimates of $1.14 by a penny, they missed consensus numbers when it came to revenue for the fourth quarter. While analysts were looking for $17.86 billion in revenue, the company came slightly shy of this figure, reporting $17.81. When compared to the same quarter the prior year, the company beat the EPS number of $0.89 by a long shot, but came in shy of the $18.25 billion revenue figure from Q4, 2014.
“As we enter 2016, our core business is very healthy, and the recent decisive actions we’ve taken in support of each of our businesses position us well to drive sustainable long-term growth, faster than the markets we compete in,” explained company CEO and chairman Alex Gorsky.
The stock decreased 0.32% or $0.31 on January 26, hitting $96.44. Approximately 550 shares traded hands. JNJ shares have declined 3.46% since June 19, 2015 and are currently downtrending. It has outperformed the S&P500 by 5.40%.
From a total of 8 analysts covering Johnson & Johnson (NYSE:JNJ) stock, 5 rate it a “Buy”, 0 a “Sell”, and 3 a “Hold”. This means that 63% of the ratings are positive. The highest target price is $120 while the lowest target price is $90. The mean of all analyst targets is $108.27 which is 12.27% above today’s ($96.44) stock price. Johnson & Johnson was the topic of 16 analyst reports since August 7, 2015 according to the firm StockzIntelligence Inc. Atlantic Securities initiated shares on December 18 with a “Neutral” rating. Vetr downgraded shares to a”Strong-Buy” rating and a $106.73 target share price in their report from an August 31. S&P Research maintained JNJ stock in a recent report from October 14 with a “Buy” rating. Cowen & Co maintained the rating on August 25. Cowen & Co has a “Outperform” rating and a $114 price target on shares. Finally, Piper Jaffray reinitiated the stock with a “Neutral” rating in a report they issued on an October 5.
The institutional sentiment increased to 1.22 in Q2 2015. It’s up 0.26, from 0.96 in 2015Q2. The ratio improved, as 67 funds sold all their Johnson & Johnson shares they owned while 732 reduced their positions. 85 funds bought stakes while 888 increased their total positions. Institutions now own 1.79 billion shares which is 0.52% more than the previous share count of 1.78 billion in 2015Q2.
Robert Wood Johnson Foundation holds 99.86% of its total portfolio in Johnson & Johnson, equating to 13.00 million shares. Pettee Investors Inc. owns 159,596 shares representing 15.59% of their total US portfolio. Moreover, Cincinnati Indemnity Co has 11.49% of their total portfolio invested in the company, equating to 25,000 shares. The Connecticut-based Tweedy Browne Co Llc has a total of 10.72% of their portfolio invested in the stock. Sector Gamma As, a Norway-based fund reported 420,100 shares owned.
Since March 9, 2015, the stock had 0 buys, and 1 sale for a total of $621,904 in net activity. Kapusta Ronald A sold 6,239 shares worth $621,904. Stoffels Paulus sold 187,250 shares worth $18.86 million. Fasolo Peter sold 115,307 shares worth $11.81M.
Johnson & Johnson is a holding company. The company has a market cap of $267.70 billion. The Firm is engaged in the research and development, manufacture and sale of a range of products in the health care field. It has 18.48 P/E ratio. The Firm has more than 265 operating companies conducting business around the world.